January 07, 2020
Oncopeptides strengthens its regulatory function by appointing Karin Eklund Vanderpol as Head of Regulatory Affairs
Media
December 20, 2019
GenSight Biologics obtains €15 million in financing through a bond issuance from Kreos Capital and a reserved capital increase from Sofinnova and 3SBio
December 18, 2019
BONESUPPORT appoints Kristina Ingvar to Executive Vice President Quality Management & Regulatory Affairs
December 18, 2019
Update on progress for drug development programs VP01 (C21) and VP02 (IMiD)
December 18, 2019
Nordic Nanovector awarded NOK 12 million in funding from the Norwegian Research Council to advance Alpha37, a targeted alpha therapy for B-cell cancers
December 17, 2019
Bulletin from the Extraordinary General Meeting in Oncopeptides AB (publ)
December 12, 2019
SVCA:s pris för Årets affär går till HealthCap VI LP för sin avyttring av Wilson Therapeutics AB
December 12, 2019
Nordic Nanovector provides update on LYMRIT 37-05 Phase 1 DLBCL trial
December 11, 2019
GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history
December 09, 2019
The Quinze-Vingts Hospital and GenSight Biologics announce a first Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France